Antifungal resistance is an increasing concern in the treatment of fungal infections, especially when there are already limited options in the treatment paradigm. It was a pleasure to talk with Editorial Board member Prof. Mahmoud Ghannoum (Integrated Microbiome Core and Center for Medical Mycology, Cleveland, OH, USA) around the impact of biofilms on antifungal therapy, how in vitro resistance and tolerance phenomena affect treatment outcomes, the challenges in diagnosing and treating fungal infections and the development of new therapeutic strategies to combat antibiotic resistance.
Interviews in this series:
Ibrexafungerp against Mucor strains using time-kill and scanning electron microscopy
ECCMID 2023 highlights in fungal infections
The session ‘What really matters in antifungal resistance’ was presented at ECCMID 2023, 15-18 April, 2023, Copenhagen, Denmark.
Questions
- How does the presence of biofilms impact the effectiveness of antifungal therapy?
- What are some of the key differences between mechanisms of in vitro resistance and tolerance phenomena, and how do these differences impact treatment outcomes in fungal infections?
- What are the challenges in diagnosing and treating fungal infections that exhibit tolerance or biofilm formation?
- What role does advancing knowledge of antifungal resistance play in the development of new therapeutic strategies for the treatment of fungal infections?
Disclosures: Mahmoud Ghannoum is a consultant for Ortho Dermatologics.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Katey Gabrysch.
Filmed in coverage of the 33rd European Congress of Clinical Microbiology & Infectious Diseases.
Click here for more content on fungal infections & for further ECCMID 2023 highlights visit here.
